Early observations and pilot data that first suggested a new direction
LEADER tested cardiovascular outcomes when liraglutide was added to standard care in type 2 diabetes. Among 9,340 patients at high cardiovascular risk, the first cardiovascular death, nonfatal MI or nonfatal stroke occurred in 13.0% with liraglutide versus 14.9% with placebo over a median 3.8 years (HR 0.87, 95% CI 0.78–0.97). This demonstrated a cardiovascular outcome benefit in the tested population, extending the clinical question beyond glucose levels alone.
Landmark RCTs and pivotal trials that established the evidence base
SUSTAIN-6 randomized 3,297 patients with type 2 diabetes to once-weekly semaglutide or placebo for 104 weeks. Cardiovascular death, nonfatal MI or nonfatal stroke occurred in 6.6% versus 8.9% (HR 0.74, 95% CI 0.58–0.95). STEP 1 studied 1,961 adults with overweight or obesity without diabetes: semaglutide 2.4 mg plus lifestyle intervention produced a mean 14.9% weight reduction at 68 weeks versus 2.4% with placebo. These trials address distinct cardiovascular and weight outcomes.
Follow-up studies, subgroup analyses, and real-world validation
SELECT enrolled 17,604 patients with established cardiovascular disease and overweight or obesity but no diabetes. At a mean follow-up of 39.8 months, the primary cardiovascular endpoint occurred in 6.5% with semaglutide versus 8.0% with placebo (HR 0.80; 95% CI 0.72–0.90). FLOW enrolled 3,533 patients with type 2 diabetes and chronic kidney disease. Major kidney disease events were 24% lower with semaglutide than placebo. FLOW reported early cessation at a prespecified interim analysis; that statement should not be extended to SELECT.
Integration into clinical practice guidelines and recommendations
ADA/EASD 2022 applies to non-pregnant adults with T2D. Use proven-benefit GLP-1 RA for MACE reduction in established CVD; consider it with multiple CV risk factors. Decisions are independent of HbA1c/metformin. Use SGLT2i for HF; in CKD, initiate proven-benefit SGLT2i if eGFR ≥20 mL/min/1.73 m² and UACR >30 mg/g (regional indications vary). If not tolerated or contraindicated in CKD, consider GLP-1 RA with proven CV benefit to reduce MACE.
ADA/EASD
In T2D, consider GLP-1 RA before insulin if no contraindications; use proven-benefit GLP-1 RA to reduce MACE in established CVD.
ADA/EASD consensus
Consider GLP-1 RA before insulin in T2D when no contraindications; they are contraindicated with personal/family medullary thyroid cancer or MEN2. Do not delay indicated insulin. Insulin may be preferred for severe hyperglycemia (HbA1c >10%), especially with weight loss/ketosis, acute glycemic dysregulation, underweight or suspected type 1 diabetes.
Now
Current standard of care and ongoing research directions
FLOW extends the evidence to clinically important kidney outcomes in type 2 diabetes with chronic kidney disease. Semaglutide reduced major kidney disease events, slowed the annual decline in eGFR and reduced cardiovascular and all-cause mortality in this population. The practical question is how to select patients and balance these benefits with treatment burden and tolerability.
Do GLP-1 receptor agonists provide cardiovascular benefit in patients without diabetes?+
SELECT studied 17,604 patients with established cardiovascular disease and overweight or obesity without diabetes. Weekly semaglutide 2.4 mg reduced cardiovascular death, nonfatal MI or nonfatal stroke versus placebo (HR 0.80, 95% CI 0.72–0.90; P<.001).
What kidney benefits have been demonstrated with GLP-1 receptor agonists?+
FLOW found 24% lower major kidney disease event risk with semaglutide in type 2 diabetes and CKD (HR 0.76, 95% CI 0.66–0.88). Kidney-specific components had HR 0.79; cardiovascular death had HR 0.71. Early cessation was recommended at a prespecified interim analysis.
How much weight loss can be expected with semaglutide for obesity?+
In STEP 1, semaglutide 2.4 mg plus lifestyle intervention produced mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo in adults with overweight or obesity without diabetes. At least 5% weight loss occurred in 86.4% with semaglutide.